ReviewDrugs2006
Orlistat: a review of its use in the management of obesity.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- [Cardiovascular preventive recommendations. PAPPS 2024 thematic updates].Atencion primaria · 2024Guideline
- A large-scale genome-wide cross-trait analysis reveals shared genetic architecture between Alzheimer's disease and gastrointestinal tract disorders.Communications biology · 2022Pooled it
- Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose.Clinical pharmacology in drug development · 2021Trial
- Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study.Obesity facts · 2017Trial
- Mechanistic Insights into Pancreatic Lipase Inhibition by Sugarcane Polyphenols: A Structural and Kinetic Study.Foods (Basel, Switzerland) · 2026Article
- Pharmacological inhibition of IRAK1/4 ameliorates high-fat diet-induced vascular dysfunction and cognitive impairment.Molecular biology reports · 2026Article
- Effect of anti-obesity drug orlistat (Xenical™) on liver and kidney function in male rats fed a high-fat diet.F1000Research · 2026Article
- Dietary sphingolipids and milk fat globule membrane: emerging roles in cardiometabolic health and muscle function.Food science and biotechnology · 2025Review
- Challenges in the Investigation of Therapeutic Equivalence of Locally Applied/Locally Acting Drugs in the Gastrointestinal Tract: The Rifaximin Case.Pharmaceutics · 2025Review
- Integrating machine learning and structure-based approaches for repurposing potent tyrosine protein kinase Src inhibitors to treat inflammatory disorders.Scientific reports · 2025Article
- Intestinal epithelial cell NCoR deficiency ameliorates obesity and metabolic syndrome.Acta pharmaceutica Sinica. B · 2024Article
- Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.BMC pharmacology & toxicology · 2024Article
- Graphene oxide as inhibitor on the hydrolysis of fats under simulated in vitro duodenal conditions.Heliyon · 2024Article
- A nanoemulsion targeting adipose hypertrophy and hyperplasia shows anti-obesity efficiency in female mice.Nature communications · 2024Article
- Exploring the anti-obesity bioactive compounds ofRSC advances · 2023Article
- Regulation of appetite-related neuropeptides by Panax ginseng: A novel approach for obesity treatment.Journal of ginseng research · 2022Review
- UHPLC-DAD Characterization ofMolecules (Basel, Switzerland) · 2021Article
- Use of Silica Based Materials as Modulators of the Lipase Catalyzed Hydrolysis of Fats under Simulated Duodenal Conditions.Nanomaterials (Basel, Switzerland) · 2020Article
- The risk of cardiovascular complications with current obesity drugs.Expert opinion on drug safety · 2020Review
- Role of Cannabinoids in Obesity.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data have shown that orlistat is also effective as a component of weight management strategies in obese adolescents. In addition to its well established efficacy in achieving modest weight loss, orlistat has been shown to improve glycaemic parameters in obese adults with type 2 diabetes mellitus as well as some features of the metabolic syndrome. Orlistat is generally well tolerated. Thus, orlistat is an option for the treatment of obese patients with or without type 2 diabetes and also has a role in the management of obese patients with the metabolic syndrome, associated comorbidities or concomitant disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.